Institution identification

Institution ID

3331431

Institution full name and acronym

Erasmus Medical Centre Rotterdam

ENCePP partner

No
Institution description
No information provided.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A Post-Authorisation Disease Registry Safety Study to Generate Data on the Long-Term Safety and Clinical Effectiveness of SCENESSE® (Afamelanotide 16mg) in Patients with Erythropoietic Protoporphyria (EPP) (SCENESSE® PASS-001)
ADVANCE POC I Risk pillar - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of safety outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children
Adverse events and inefficacy of PCSK9 Inhibition with evolocumab or alirocumab in hypercholesTeraemic pAtients. (AKITA)
Arrhythmogenic Potential of Drugs (ARITMO) project
CharacTeristics of treAtment response to hIgh dose ICS/LABA vs. Medium or high dOse ICS/LABA + LAMA in patients with uncontRolled moderate to severe asthma on medium dose ICS/LABA - TAILOR study
Clinical features of COVID-19 in Pediatric Patients (COPP-study)
Drug utilisation studies using data mapped to the OMOP Common Data Model: a proof of concept study assessing respiratory drug use in patients with asthma or COPD
LOWER: Lomitapide Observational Worldwide Evaluation Registry (AEGR-733-025)
Multinational, multi-database drug utilization study of indacaterol/glycopyrronium bromide in Europe
Patterns and Determinants of Use of Oral Contraceptives in the European Union (Use of OC in the EU)
Postauthorisation Safety Study (PASS) of Avatrombopag in Patients With Severe Chronic Liver Disease (CLD)
Prospective, multi-country, observational registry to collect clinical
Risk of cardiac valve disorders associated with the use of biphosphonates (Cardiac valve disorders and biphosphonate use)
Safety Evaluation of Adverse Reactions in Diabetes - Comparative studies (SAFEGUARD)
Safety Evaluation of Adverse Reactions in Diabetes - Drug utilisation studies (SAFEGUARD)
SCENESSE® (Afamelanotide 16mg) Retrospective Chart Review (SCENESSE® Chart Review)
The comparative safety of first-line conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study
Utilisation disease-modifying anti-rheumatic drugs (DMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study